Jakafi failed the primary endpoint in a Covid-19 study. But Incyte is still going to FDA with a compassionate use pitch
Jakafi disappointed Incyte once when it failed to prevent severe complications of Covid-19. The JAK inhibitor has fallen short again in another Phase III study, failing to keep a more critical subgroup of patients from dying.
The DEVENT study recruited 211 people with acute respiratory distress syndrome on mechanical ventilation, and set out to see if either a 5mg dose or a 15mg dose of Jakafi could reduce mortality through day 29 compared to standard of care alone. In today’s world, that means remdesivir for 55% of study patients and corticosteroids for 90%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
